Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 4;30(4):oyaf004.
doi: 10.1093/oncolo/oyaf004.

Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors

Paulo S do Amaral  1 , Kathryn E Beckermann  1 , Jennifer B Gordetsky  1 , Sam S Chang  1 , Daniel D Joyce  1 , Kerry Schaffer  1 , Amy N Luckenbaugh  1 , Morgan A Lambrecht  1 , Elizabeth G Ryan  1 , Daniel A Barocas  1 , Kelvin A Moses  1 , Brian I Rini  1
Affiliations

Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors

Paulo S do Amaral et al. Oncologist. .

Abstract

Background and objective: Cytoreductive nephrectomy following immune checkpoint blockade (ICB) in metastatic renal cell carcinoma remains controversial, with limited data on its clinical and pathological outcomes. This study evaluated the outcomes of patients undergoing deferred cytoreductive nephrectomy (dCN) after ICB-based treatment, focusing on the radiologic and pathological responses, and postoperative clinical outcomes.

Methods: We retrospectively reviewed 24 patients with metastatic or locally advanced RCC who underwent dCN after ICB at a single institution between April 2018 and May 2024. We assessed the radiological response to ICB, pathological findings (presence and extent of necrosis) in resected primary tumors, and postoperative clinical outcomes, including the rate of patients without measurable disease and those who discontinued systemic therapy.

Results: Median ICB exposure prior to surgery was 11.3 months. Radiologically, 67% of patients had partial response, 29% had stable disease, and 4% had a complete response. Pathology showed 96% of specimens with necrosis, 21% of specimens showing no residual disease (pT0), and 21% exhibiting ≥95% necrosis. Postoperatively, 50% of patients had nonmeasurable disease of first follow-up scans, and 54% discontinued systemic therapy, with 9 patients remaining on surveillance at last follow-up. Limitations include the small sample size and retrospective design.

Conclusion: Deferred CN following ICB therapy is feasible. Extensive necrosis in the resected surgical specimen after ICB-based therapy requires further investigation as a prognostic marker for durable responses off systemic therapy.

Keywords: deferred cytoreductive nephrectomy; immunotherapy; kidney cancer; necrosis; treatment de-escalation.

PubMed Disclaimer

Conflict of interest statement

K.B. served as consultant to Alpine Bioscience, Aveo, Aravive, Adicet, Astrazeneca, Exelixis, BMS, Merck, Xencor, Arcus, Eisai, and Nimbus. K.A.M. received honoraria from Boston Scientific-Data Safety Monitoring Comitee. The remaining authors have no COI to declare.

Figures

Figure 1.
Figure 1.
Follow-up of patients with extensive necrosis (≥95%) after dCN.
Figure 2.
Figure 2.
Follow-up of patients without extensive necrosis (<95%) after dCN.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Flanigan RC, Salmon SE, Blumenstein BA, et al.Nephrectomy followed by interferon Alfa-2b compared with interferon Alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659. https://doi.org/10.1056/NEJMoa003013 - DOI - PubMed
    1. Mickisch G, Garin A, van Poppel H, de Prijck L, Sylvester R.. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. The Lancet. 2001;358:966-970. https://doi.org/10.1016/s0140-6736(01)06103-7 - DOI - PubMed
    1. Flanigan RC, Mickisch G, Sylvester R, et al.Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071-1076. https://doi.org/10.1097/01.ju.0000110610.61545.ae - DOI - PubMed
    1. Méjean A, Ravaud A, Thezenas S, et al.Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417-427. https://doi.org/10.1056/NEJMoa1803675 - DOI - PubMed
    1. Méjean A, Ravaud A, Thezenas S, et al.Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;80:417-424. https://doi.org/10.1016/j.eururo.2021.06.009 - DOI - PubMed

Substances